Des scientifiques marseillais font avancer la recherche contre le cancer du sein

A powerful scientific platform opens new possibilities for treating cancer, autoimmune diseases, and other conditions in which reprogrammed T cells could provide a benefit to patients.

Adaptam Therapeutics, a Spanish biotech startup, has secured €3 million in a pre-seed financing round. Criteria Bio Ventures led this investment. The funds will speed up development of the company's first-in-class antibody-based therapies. These include antibody-drug conjugates and bispecific antibodies. The therapies target multiple forms of cancer. This funding marks a key milestone for Adaptam. It positions the firm to tackle tough challenges in oncology.

Roswell Park is dedicated to accelerating access to the most promising immunotherapy treatments through clinical trials. Few institutions in the nation have the facilities for pre-treatment, manufacturing and post-treatment of immunotherapies and gene therapy clinical trials. With a recent investment from New York State and with the support of donors through the Igniting Cancer Breakthroughs campaign, Roswell Park has all of this, making it uniquely positioned to lead cutting-edge trials.

Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE), is driven by immune complex deposition and complement activation, resulting in glomerular inflammation and podocyte injury. Beyond being passive targets, podocytes actively modulate renal immunity through cytokine se …

Adaptam aims to expand its pipeline and prepare for further fundraising as it moves toward clinical development.

Les vaccins à ARN-m contre le Covid-19 améliorent l’efficacité de certains traitements immunitaires. Le lien observé entre la vaccination contre le Covid et l’augmentation du taux ...

Diakonos Oncology Corp., a clinical-stage biotechnology company focused on innovative cancer immunotherapies, will showcase preliminary data from its Phase I clinical trial of DOC1021, a novel cell-based immunotherapy, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting in National Harbor, Maryland, from November 5-9, 2025. The presentation will highlight early results from the trial targeting resectable or borderline resectable pancreatic ductal adenocarcinoma, a cancer with significant unmet treatment needs.

Offenbar lösen die in der Pandemie millionenfach verabreichten mRNA-Vakzine einen Turbo-Effekt bei Krebsimmuntherapien aus. Ist das der Beginn einer neuen Ära der Onkologie?

OSE Immunotherapeutics, société spin-off de Nantes Université en biotechnologie et immunothérapies innovantes et cotée sur Euronext Paris, signe avec Inserm Transfert et Nantes Université un accord de...